Welcome to our dedicated page for Generate Biomedicines SEC filings (Ticker: GENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Generate Biomedicines, Inc. filings document public-company events, financial results, governance changes, capital structure, and clinical portfolio disclosures. The company's Form 8-K reports include quarterly results and business updates covering its generative biology platform and named programs such as GB-0895, GB-4362, and GB-5267.
Filings also describe IPO-related governance documents, including the amended and restated certificate of incorporation and bylaws, authorized common and preferred stock, stockholder meeting procedures, advance-notice provisions, and board authority over undesignated preferred stock. Registration and event disclosures provide formal records of the company's transition to a Nasdaq-listed clinical-stage biotechnology issuer.
Generate Biomedicines, Inc. (GENB) director Frances Arnold reported a sale of 1,000 shares of common stock on September 1, 2026 at a weighted average price of $16.002 per share, effected under a Rule 10b5-1 trading plan adopted on March 13, 2026. After this sale, she holds 231,472 shares directly and an additional 232,472 shares are held indirectly by The Frances Arnold 2010 Irrevocable Trust, for which she disclaims beneficial ownership except to the extent of any pecuniary interest.
Generate Biomedicines, Inc. (GENB) is the issuer for which director Frances Arnold has filed a notice of proposed sale of common stock under Rule 144. The filing covers a planned sale of 32,210 shares of common stock, with an aggregate market value of $520,630.62, through Fidelity Brokerage Services LLC on NASDAQ around September 2, 2026.
The shares to be sold originated from restricted stock vesting from the issuer on September 23, 2020 as compensation. The notice also reports that Arnold sold 1,000 shares during the past three months for proceeds of $16,002.00. The form is signed by Joshua Schmitt as a duly authorized representative of Fidelity, acting as attorney-in-fact for Frances Arnold.
Generate Biomedicines, Inc. (GENB) has a notice of proposed sale on file under Rule 144 for common stock held for the account of Frances Arnold. The filing indicates that 1,000 shares of common stock are planned to be sold through Fidelity Brokerage Services LLC on or about September 1, 2026. These shares were originally acquired on September 23, 2020 as restricted stock vesting from the issuer as compensation.
Generate Biomedicines, Inc. (GENB) reports that draft versions of three scientific posters on its antibody GB-0895 were inadvertently made publicly available on the European Respiratory Society (ERS) website before the expected embargo expiry. As a precaution, the company is furnishing the final posters, which summarize Phase 1 and Phase 3 program details, as an exhibit.
The Phase 1 asthma study (GB-0895-101) tests single and multiple subcutaneous doses in mild-to-moderate asthma. GB-0895 was generally well tolerated, with no treatment-related serious adverse events, a sustained, dose-proportional pharmacokinetic profile, and an estimated ~98‑day half‑life at 300 mg. Marked and durable reductions in key inflammatory biomarkers (BEC, FeNO, IL‑5, IL‑13) were observed for at least six months, with 300 mg achieving maximal biomarker suppression.
In COPD participants, single-dose GB-0895 (300 mg and 600 mg) also showed a tolerability profile with no treatment-related serious adverse events and sustained biomarker reductions for at least six months. GB-0895 is now being evaluated in two ongoing, global, randomized, double-blind, placebo-controlled Phase 3 trials, SOLAIRIA‑1 and SOLAIRIA‑2, in adults and adolescents with severe uncontrolled asthma.
Generate Biomedicines, Inc. is an AI-driven, clinical-stage biotechnology company developing protein therapeutics on its Generate Platform. Collaboration revenue was $6,314 (in thousands) in Q2 2026 and $13,538 (in thousands) year-to-date, mainly from multi-program agreements with Novartis and Amgen.
Research and development expense reached $64,330 (in thousands) in the quarter and $122,142 (in thousands) for the first half, reflecting a Phase 3 program for GB-0895 in severe asthma, a Phase 1 trial for GB-4362, and preparations for a Phase 1 trial of GB-5267. Net loss attributable to common stockholders was $67,255 (in thousands) for Q2 and $136,450 (in thousands) for the first six months, with net cash used in operating activities of $138,332 (in thousands).
Following a March 2026 IPO that generated net proceeds of $369,289 (in thousands), cash, cash equivalents and marketable securities totaled $457.4 million at June 30, 2026, and stockholders’ equity was $456,045 (in thousands). Management states that existing capital is expected to fund the current operating plan into the first half of 2028.
Generate Biomedicines, Inc. reported Q2 2026 results and a business update. Collaboration revenue was $6.3 million and the company recorded a net loss of $67.3 million, reflecting higher research and development spending. Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026, and management believes this will fund the operating plan into the first half of 2028.
The pipeline advanced with global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 studies of GB-0895 in severe asthma progressing, including regulatory approvals in 33 of a planned 42 countries and recruitment underway across six global regions. Phase 1b GB-0895 COPD data and additional asthma data will be presented at the ERS Congress 2026.
In oncology, all patients were enrolled in the first cohort of the Phase 1 study of GB-4362, which has FDA Fast Track designation, and a trial-in-progress poster is expected at ESMO 2026. A Novartis collaboration asset designed with the Generate Platform advanced into the partner’s preclinical pipeline, and a Phase 1 trial of GB-5267 CAR T in ovarian cancer is now recruiting.
Generate Biomedicines, Inc. reports Schedule 13G disclosures from Flagship-related entities showing aggregated control positions in Common Stock. The filing lists shares outstanding of 128,192,484 as of March 31, 2026. The excerpt shows Flagship Pioneering, LLC holds 62,673,117 shares (48.9%) and related Flagship vehicles hold multiple additional positions, including Flagship VentureLabs VI, LLC: 25,016,458 shares (19.5%), Flagship Pioneering Fund VII, L.P.: 16,827,224 shares (13.1%), and Flagship Pioneering Fund VI, L.P.: 12,723,940 shares (9.9%). The filing identifies the Reporting Persons, their addresses, citizenships, and the voting/dispositive power reported for each entity.
Generate Biomedicines, Inc. executive Michael Nally reported beneficial ownership of 6,919,051 shares of Common Stock, representing 5.2% of the class as of March 31, 2026. The filing cites 128,192,484 shares outstanding as of March 31, 2026. The reported stake includes 4,029,897 shares underlying stock options exercisable within 60 days and several record holdings across trusts and a GRAT. The statement is a beneficial ownership disclosure under Schedule 13G and is signed by Michael Nally on May 15, 2026.
Generate Biomedicines, Inc. reports first-quarter 2026 results as a newly public, clinical-stage biotech focused on AI-driven protein therapeutics. Collaboration revenue was $7.2 million, while operating expenses of $71.3 million led to a net loss of $61.7 million. Research and development spending rose to $57.8 million as the company advanced GB-0895 into Phase 3 severe asthma trials and prepared first-in-human studies for GB-4362 and GB-5267. Net cash used in operating activities was $80.4 million. After its IPO, which generated $369.3 million in net proceeds, cash, cash equivalents and marketable securities reached $516.6 million as of March 31, 2026, and management expects this to fund operations into the first half of 2028.
Generate Biomedicines, Inc. reported first quarter 2026 results, combining a recent IPO cash infusion with higher investment in its pipeline. Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, reflecting $369.3 million in net IPO proceeds and supporting an expected cash runway into the first half of 2028.
Collaboration revenue for the quarter was $7.2 million, while research and development expenses rose to $57.8 million and general and administrative expenses to $13.5 million, driven partly by Phase 3 work on GB-0895 and public-company costs. Net loss attributable to common stockholders widened to $69.2 million, and net cash used in operating activities was $80.4 million for the quarter.
The company highlighted continued advancement of its generative biology platform and clinical programs, including Phase 3 trials of GB-0895 in severe asthma, ongoing development in COPD, and oncology programs GB-4362 and GB-5267, with GB-4362 holding FDA Fast Track designation.